Mexican pharmaceutical manufacturer Sanfer has invested more than $40 million to expand pharmaceutical production capacity in Colombia, targeting export markets across Latin America and the Caribbean, according to a Sanfer-supported feature in Semana.

MANUFACTURING · PHARMA · SEPTEMBER 28, 2026 · COLOMBIA
A Mexican drugmaker’s expansion in Colombia is a data point for regional supply-chain planners. Sanfer, a Mexican pharmaceutical manufacturer with operations in Colombia, has invested more than $40 million to expand drug production capacity in the country, according to a Semana feature labeled “Contenido elaborado con el apoyo de Sanfer” (produced with Sanfer’s support). The company employs more than 2,000 people in Colombia, per the same report, and aims to direct about 30% of its Colombian production to international markets.
The strategic logic is visible in the production numbers. Semana reports that Sanfer’s new Colombian plant, which produced its first commercial batch in 2026, lifted annual capacity from 25 million to 84.1 million units, with a portfolio of up to 400 product references. Suany Orrego Carvajal, general director of Sanfer Colombia, presented the plant expansion when it opened in June 2024, according to El Tiempo.
The investment figure itself warrants a note on sourcing. El Tiempo reported a $35 million figure in June 2024, attributed to a new Pharmaceutical Production Center in Bogotá. The more recent figure of over $40 million, from Sanfer-supported Semana content dated September 2026, is the larger of the two reported amounts. Readers should treat the specific dollar amounts as reported, not audited, figures. The capacity (25 million to 84.1 million units) and export figures Semana cites match those reported at the plant’s June 2024 opening, which suggests the larger figure may cover the same program.
The export ambition — more than 20% of Sanfer’s Colombian output already exported to markets including Ecuador, Chile, Argentina, Mexico, Central America and the Caribbean, per Semana — places Sanfer’s expansion within a recognizable regional pattern. In the public sector, the Universidad de Antioquia’s existing Planta de Medicamentos Esenciales has already been qualified as an official supplier to the Pan American Health Organization (PAHO), according to Infobae’s February 2026 reporting on a separate government-backed facility. That precedent shows at least one Colombian plant has qualified as a PAHO supplier, though Sanfer’s private-sector route operates under different commercial and regulatory conditions.
Halcones y Palomas reported in January 2025 that Sanfer had acquired Vitalis, an injectable products company, for $280 million, and that, after closing that transaction, the company reached a 14% share of installed capacity in Colombia for certain pharmaceutical production lines. If accurate, the current investment would represent a further expansion on top of an already substantial Colombian manufacturing footprint.
One variable to monitor is regulatory throughput. The Sala Especializada de Medicamentos y Productos Biológicos (SEMPB) of Colombia’s Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA), the country’s pharmaceutical regulator, reviews new chemical entities and biological medicines; its February 2025 session record (Acta No. 02 de 2025) spans seven meeting days. If registrations lag an output ramp, that could affect which products reach export markets and when.
What to Watch
- Whether Sanfer files new or modified product registrations with INVIMA consistent with the expanded production volume, and the agency’s processing timeline for those applications
- The share of the 84.1 million unit annual capacity that is directed to export versus domestic Colombian supply, and which specific markets receive product
- Whether the Colombian government’s parallel public-sector manufacturing initiative — the 423.6 billion peso facility agreed by the Ministerio de Salud y Protección Social, the Universidad de Antioquia and the Instituto Nacional de Salud — creates competitive or complementary dynamics for private manufacturers targeting the same regional export channels
Read together, the two projects point to a possible dual-track model for Colombian pharmaceutical manufacturing: one track public, anchored in the government’s Conpes 4170 (Consejo Nacional de Política Económica y Social) 2026–2035 health sovereignty agenda, and one track private, illustrated by Sanfer’s export-oriented expansion. How those two tracks interact — on pricing, on INVIMA registration priority, on PAHO procurement eligibility — will determine whether the country’s manufacturing ambitions translate into durable supply-chain influence or remain parallel projects with limited coordination.
Sanfer’s Colombian Manufacturing Footprint
Why this is relevant
Patients
Sanfer’s stated aim of directing about 30% of Colombian production to international markets, combined with an existing 20% export share to Latin America and the Caribbean, suggests expanded local manufacturing could contribute to improved medicine availability across the region, though supply-chain and registration timelines remain determining factors.
Industry
The investment, reported at over $40 million in Sanfer-supported Semana content and by El Tiempo at $35 million for a Bogotá facility, reflects a private-sector bet on Colombia as a pharmaceutical export platform. Sanfer’s reported 14% share of installed capacity in certain Colombian pharmaceutical lines, following its acquisition of Vitalis, indicates the company is already a material player in the country’s manufacturing base.
Payers
A private manufacturer scaling to 84.1 million units of annual capacity across 400 product references could alter regional procurement dynamics, particularly if Colombian-origin products qualify for PAHO supply channels alongside the public-sector facility being developed by the Ministerio de Salud y Protección Social, the Universidad de Antioquia and the Instituto Nacional de Salud.
Regulators
INVIMA, Colombia’s pharmaceutical regulator, may face added registration and renewal demands as Sanfer expands its product portfolio to match increased production capacity. Any constraint on the agency’s review capacity could affect the pace at which new export-eligible registrations are processed.
Sources: Semana: Sanfer impulsa la producción de medicamentos en Colombia con una inversión de más de 40 millones de dólares (content produced with Sanfer’s support) · El Tiempo: Laboratorios Sanfer Colombia abrió un nuevo centro de producción · Halcones y Palomas: Grupo mexicano Sanfer llegó a 14% de participación en la capacidad instalada · Infobae: Ministerio de Salud anunció nueva planta de producción de medicamentos con una inversión de más de $420.000 millones · INVIMA: Acta No. 02 de 2025 SEMPB Cuarta parte
Related
THE HEALTHSIGNALS BRIEF
A fortnightly PDF compiling our analysis on pharma, medical devices, health policy and epidemiology across Latin America and the United States.
Built for pharma, market-access, regulatory, policy and investor teams, with the main findings of our gated reports included.




